Brandon Reid Rosen

This inventor holds 20 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Cancer Therapeutics. Top assignees: Arcus Biosciences, Inc., Other. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brandon Reid Rosen. Retrieved from https://idiyas.com/inventor/brandon-reid-rosen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 7 (Patent Applications = 13)

Average Co-Inventor Count = 9.9

ph-index = 4

Forward Citations = 74(Granted Patents)

Location History:

San Mateo, PA (US) (2021)
San Mateo, CA (US) (2019 - 2024)

Company Filing History:

19 out of 40

Arcus Biosciences, Inc.

patents

1 out of 834,513

Other

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Aminopyrimidine Compounds

5'-Nucleotidase Modulators

HIF-2α Inhibitors

Azolopyrimidine

Quinazoline Derivatives

Cancer Treatment

Tetralin Compounds

Adenosine Inhibitors

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630526 - Processes for preparing aminopyrimidine compounds (2026-05-19),

2. 12459967 - Modulators of 5'-nucleotidase, ecto and the use thereof (2025-11-04),

3. 12226425 - Inhibitors of ARG1 and/or ARG2 (2025-02-18),

4. 12195447 - Azolopyrimidine for the treatment of cancer-related disorders (2025-01-14),

5. 12168023 - Inhibitors of adenosine 5'-nucleotidase (2024-12-17),

6. 12145901 - Process for preparing tetralin compounds (2024-11-19),

7. 12103907 - Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha (2024-10-01),

8. 12071411 - Inhibitors of HIF-2α and methods of use thereof (2024-08-27),

9. 12064433 - Pyridone A2R antagonists (2024-08-20),

10. 11787762 - Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha (2023-10-17),

11. 11667662 - Modulators of 5'-nucleotidase, ecto and the use thereof (2023-06-06),

12. 11407712 - Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α (2022-08-09),

13. 11220492 - Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders (2022-01-11),

14. 11072597 - Azolopyrimidine for the treatment of cancer-related disorders (2021-07-27),

15. 11058704 - Inhibitors of adenosine 5'-nucleotidase (2021-07-13),

Title: Exploring the Innovations of Brandon Reid Rosen

Introduction: Brandon Reid Rosen is an accomplished inventor based in San Mateo, California, with an impressive portfolio of 18 patents. His contributions to the fields of medicinal chemistry and pharmaceutical innovation have the potential to significantly impact the treatment of various diseases, disorders, and conditions.

Latest Patents: Among his latest innovations, Rosen has developed compounds that serve as inhibitors of ARG1 and/or ARG2. These compounds are not only pivotal in synthesizing methods but also hold promise for treating a diverse range of diseases, including cancer and immune-related disorders that are mediated by ARG1 and ARG2. Additionally, he has created an azolopyrimidine compound that acts as an inhibitor of adenosine receptors. This compound, along with its compositions and synthesis methods, aims to address cancer-related conditions and other ailments that are influenced by the adenosine receptors.

Career Highlights: Throughout his career, Brandon has made significant strides in the pharmaceutical industry. His work at Arcus Biosciences, Inc. has been particularly noteworthy, as he has played a vital role in advancing research and development in therapeutic innovations.

Collaborations: Collaboration is key in research and development, and Rosen has partnered with accomplished professionals in the field. Notable coworkers include Manmohan Reddy Leleti and Jay Patrick Powers, both of whom contribute to the innovation landscape surrounding biotechnology and pharmaceuticals.

Conclusion: Brandon Reid Rosen's ongoing contributions through his patents and collaborative efforts illustrate his commitment to advancing medical science. His work continues to pave the way for new treatments and potential breakthroughs in addressing critical health issues. As he progresses in his career, the impact of his innovations is expected to resonate within the medical and scientific communities.

Profile summary based on public USPTO records.